Form 4: Fulcrum Therapeutics Executive Granted Stock Options

Curtis Gale Oltmans, Chief Legal Officer of Fulcrum Therapeutics, received stock options for 225,000 shares on January 24, 2025, vesting quarterly over four years.

Summary

• Curtis Gale Oltmans, the Chief Legal Officer of Fulcrum Therapeutics, was granted stock options on January 24, 2025.
• The options are for 225,000 shares of Fulcrum Therapeutics common stock.
• The exercise price of the options is $4.16 per share.
• The options vest in equal quarterly installments over four years, starting January 1, 2025, contingent upon continued service.
• The options expire on January 24, 2035.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• Vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, similar to companies like Vertex Pharmaceuticals and Biogen.
• The vesting schedule of four years with quarterly installments is also typical.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates